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S188 Oral PresentationsIn NOD/SCID-b2-microglobulinnull (NSb) mice, human
ALDHbr cells also established short-term human myeloid develop-
ment, including CD41+ platelets. In contrast, engraftment by total
CB was very low. However, human hematopoietic chimerism in-
creased .10-fold when total CB was augmented 4 hours later with
ALDHbr progenitors. By using HLA-matched (6/6), but sex-
mismatched CB, continuing studies will examine the relative contri-
butions of the ALDHbr cells and the total CB.
Unmanipulated CB did not yield efficient short-term myeloid en-
graftment in either NOD/SCID strain. In contrast, ALDHbr pro-
genitors established human myeloid development in both strains.
Furthermore, ALDHbr cells altered the outcome of CB transplants
in two distinct ways. In NSg mice, the ALDHbr progenitors facili-
tated either the engraftment or the proliferation of T cells. In NSb
mice, ALDHbr progenitors appeared to directly augment short-
term myeloid engraftment by total CB. Importantly, the latter stud-
ies reflect the clinical experience of early CBT trials that use this
strategy.
Hematopoietic chimerism in NSg and NSbmice
NOD/SCID Chimerism,
strain Graft %huCD4516 SD CompositionNSg ALDHbr 126 4.9% (n5 5) Myeloid and B cells
NSg CB 7.46 4.7% (n5 8) T cells
NSg CB 1ALDHbr 18.96 9.3% (n5 10) T cells
NSb ALDHbr 5.66 4.7% (n5 5) Myeloid and B cells
NSb CB 0.326 0.19% (n5 4) \detection limit
NSb CB 1ALDHbr 4.36 1.9% (n5 5) Myeloid and B cellsFor each mouse strain, the level of human hematopoietic chimerism
achieved within the bone marrow is provided for each cohort. The gen-
eral composition of the human progeny within the bone marrow is also
given.SUPPORTIVE CARE
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Background: IFI are significant causes of morbidity and death af-
ter HCT. Optimal antifungal prophylaxis following HCT is un-
certain. The potential of oral voriconazole required prospective
randomized evaluation. Itraconazole oral solution is a mold-active
agent with evidence for efficacy and documented safety in HCT
patients.
Methods: Prospective, open-label, multicenter study for primary
IFI prophylaxis after allogeneic HCT. Patients .5 12 years
were randomized (stratified by conditioning regimen intensity
and donor type) to receive oral voriconazole or oral itraconazole
from the day of HCT for at least 100 and up to 180 days. Pri-
mary composite endpoint was success of prophylaxis at Day
180, i.e. patient survived without developing proven/probable
IFI or discontinuing prophylaxis for.14 days during the
first 100 days. The study was powered to demonstrate non-
inferiority at day 180. If non-inferiority was shown, superiority
was tested.Results: 234 patients were randomized and treated with vorico-
nazole and 255 with itraconazole; all received.1 dose of study
drug. Success of prophylaxis was significantly higher with vori-
conazole than with itraconazole at Days 100 (55% vs 41%; ad-
justed for conditioning regimen and relatedness of donor 95%
CI for difference: 6%, 24%; p5 0.0007) and 180 (49% vs
35%; adjusted 95% CI for difference: 7%, 24%; p5 0.0004).
Significantly more voriconazole than itraconazole (54% vs
40%; p5 0.0014) patients had sufficient days of prophylaxis
(median: 97 vs 68 days). IFI incidence was low in both arms
(voriconazole: 1.3%, itraconazole: 2.4%); no patients developed
IFI while receiving voriconazole, compared with 3 itraconazole
patients (p5 0.08). There was no difference in survival at Day
100 and 180 (94% and 85% in both arms at respective time-
points). 1-year survival was 75% and 69% in voriconazole
and itraconazole arms respectively (p5 0.1256 for the difference
in proportions). The most common treatment-related adverse
events for voriconazole and itraconazole, respectively, were
vomiting (4% vs 16%), nausea (8% vs 15%), diarrhea (4% vs
11%), hepatotoxicity/liver function test abnormalities (12% vs
5%) and visual impairment (6% vs 0%) (p\5 0.01 for all com-
parisons).
Conclusions: Success of prophylaxis was significantly higher with
voriconazole than itraconazole. Primary prophylaxis with voricona-
zole is an effective, safe option for preventing IFI after allogeneic
HCT.
IFIs during study
Treatment Body Site
EORTC criteria Emergent* Pathogen of IFI3 in Voriconazole arm
Proven No Candida krusei Blood
Proven No Candida parapsilosis Blood
Probable No Aspergillus fumigatus Lung6 in Itraconazole arm
Proven Yes Candida glabrata Blood
Proven No Aspergillus fumigatus Lung
Probable Yes Aspergillus sp Lung
Probable Yes Aspergillus sp Lung
Probable No Aspergillus fumigatus Lung
Probable No Aspergillus sp LungTreatment-emergent IFIs: Voriconazole 0%, Itraconazole 1.2% (p5 0.08 for
difference).
*Treatment-emergent IFIs: occurring any time while patient was on
study drug and for 7 days following treatment discontinuation.90
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Background: Although screening of patients’ vital organ function
is routinely performed prior to autologous or allogeneic hemato-
poietic stem cell transplantation (HSCT), the lowest acceptable
threshold for function is not well defined. As a consequence, pa-
tients with significant organ dysfunction are often excluded from
transplantation. In order to make transplantation an option for
the maximum number of patients, retrospective studies have
been conducted to determine the impact of organ dysfunction
on transplantation outcome. The implication of transplanting pa-
tients with coronary artery disease (CAD) is one such area for
which there is no published data.
